drugset / Trial / NCT00006223
flt3L in Treating Patients With Acute Myeloid Leukemia
Phase 3
Completed
Eastern Cooperative Oncology Group
Cancer and Leukemia Group B · collabNational Cancer Institute (NCI) · collabSWOG Cancer Research Network · collab
RandomizedTreatment
Summary
RATIONALE: Drugs such as flt3L may stimulate a person's immune system and help kill cancer cells. It is not yet known if flt3L is effective in treating acute myeloid leukemia. PURPOSE: Randomized phase III trial to determine the effectiveness of flt3L in treating patients who have acute myeloid leukemia that is in remission.
Timeline
- Start
- 2000-07
- Primary completion
- —
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | flt3 ligand | Protein / enzyme biologic | — | Subcutaneous |